BIO Asia–Taiwan 2025 亞洲生技大會

Leading the Future of

Healthcare Innovation

This high-impact special session brings together global biopharma leaders and R&D experts to explore how cutting-edge innovation is reshaping the future of medicine—from next-generation cancer therapies and rare disease acceleration to tech-driven drug discovery. Join us to gain exclusive insights and connect with executives from Chugai, Novartis, GSK, CMIC, and Labcorp.

Speakers Include:

Opening Remarks

▶Johnsee Lee, Chairman, BIO Asia–Taiwan 2025
▶Grant Hu, President, IRPMA; CEO & President, Eisai Taiwan

Keynote Presentations

▶Yuji Habara, President & General Manager, Chugai Pharma Taiwan

▶Stephen Moran, Global Program Head Clinical Development & Radiopharmaceuticals Platform Lead, Novartis

▶Tina Graves, VP and General Manager, GSK Taiwan

▶Sayaka Fukura, Deputy Head, Clinical Operations Division, CMIC

Don’t miss the opportunity to explore how technology is transforming the future of healthcare—driving faster drug discovery, advancing breakthrough treatments like radioligand therapy for cancer, and accelerating progress in rare disease solutions. This session also showcases forward-thinking approaches to disease prevention, paving the way toward a healthier, more proactive global healthcare system.

Register Now & Save $100
Deadline: July 15